Carboplatin plus etoposide in heavily pretreated castration-resistant prostate cancer patients

被引：0

作者：

Buonerba, Carlo ^{[1
]}

Federico, Piera ^{[2
]}

Bosso, Davide ^{[1
]}

Puglia, Livio ^{[1
]}

Policastro, Tania ^{[1
]}

Izzo, Michela ^{[1
]}

Perri, Francesco ^{[1
]}

Scarpati, Giuseppina Della Vittoria ^{[1
]}

Ferro, Matteo ^{[3
]}

De Cobelli, Ottavio ^{[3
]}

De Placido, Sabino ^{[1
]}

Aieta, Michele ^{[4
]}

Imbimbo, Ciro ^{[5
]}

Longo, Nicola ^{[5
]}

Di Lorenzo, Giuseppe ^{[1
]}

机构：

[1] Univ Naples Federico II, Genitourinary Canc Sect, Div Med Oncol, Dept Clin Med, Naples, Italy

[2] IOS & Coleman, Naples, Italy

[3] European Inst Oncol, Div Urol, Milan, Italy

[4] IRCCS, Unit Oncol, Referral Canc Ctr Basilicata, Rionero In Vulture, Italy

[5] Univ Naples Federico II, Div Urol, Naples, Italy

来源：

FUTURE ONCOLOGY | 2014年 / 10卷 / 08期

关键词：

abiraterone; carboplatin; enzalutamide; etoposide; neuroendocrine; prostate cancer; PHASE-II; NEUROENDOCRINE DIFFERENTIATION; IMMUNOTHERAPY;

D O I：

10.2217/FON.14.71

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aims: Carboplatin plus etoposide has modest efficacy in docetaxel-pretreated castration-resistant prostate cancer patients. We hypothesized that carboplatin-etoposide could still exert some therapeutic activity after docetaxel, cabazitaxel and either abiraterone or enzalutamide. Patients & methods: We enrolled 15 patients in the first step of a Phase II trial. The target sample size is 46 patients. The primary end point of the study was progression-free survival after 12 weeks. Results: The median progression-free survival was 11 weeks (range: 8-18), while median overall survival was 18 weeks (range: 12-26). Of seven patients with measurable disease, two had a partial response, two showed stable disease and the remaining three had progressive disease as the best radiological response. Five patients were considered progression-free after 12 weeks, prompting continuation of the trial. Conclusion: Our preliminary findings support the hypothesis that carboplatin plus etoposide may yield some clinical benefit in a population of patients who failed all currently approved therapeutic options for prostate cancer.

引用

页码：1353 / 1360

页数：8

共 19 条

[1] Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer [J].